Dr. Hari on Current State of Frontline Therapy in Myeloma

Parameswaran Hari, MD, MRCP
Published: Wednesday, May 22, 2019



Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the current state of frontline therapy in multiple myeloma.

The frontline treatment of patients with myeloma is changing, says Hari. Physicians have been fortunate to have several new classes of drugs that have been FDA approved in the past 5 to 6 years. Now, patients have access to immunomodulatory agents, proteasome inhibitors, steroids, alkylators, and antibodies, with more to come, he adds. Due to the advances made with frontline therapy, more patients are achieving complete responses (CRs), stringent CRs, and even minimal residual disease negativity.

Now, the goal of frontline therapy is to reach a deep remission, whereas a decade ago the primary concern was to achieve some sort of disease control, explains Hari. If patients receive a transplant, that translates into a more prolonged progression-free survival (PFS). The field may get to a point where transplant becomes optional. However, to date, studies have shown that transplant is the best way of achieving a long PFS, he concludes.
SELECTED
LANGUAGE


Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the current state of frontline therapy in multiple myeloma.

The frontline treatment of patients with myeloma is changing, says Hari. Physicians have been fortunate to have several new classes of drugs that have been FDA approved in the past 5 to 6 years. Now, patients have access to immunomodulatory agents, proteasome inhibitors, steroids, alkylators, and antibodies, with more to come, he adds. Due to the advances made with frontline therapy, more patients are achieving complete responses (CRs), stringent CRs, and even minimal residual disease negativity.

Now, the goal of frontline therapy is to reach a deep remission, whereas a decade ago the primary concern was to achieve some sort of disease control, explains Hari. If patients receive a transplant, that translates into a more prolonged progression-free survival (PFS). The field may get to a point where transplant becomes optional. However, to date, studies have shown that transplant is the best way of achieving a long PFS, he concludes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x